10-Q

                      UNITED STATES
          SECURITIES AND EXCHANGE COMMISSION
                Washington, D.C. 20549

                        FORM 10-Q

(Mark One)
  X   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For quarterly period ended September 30, 2013

      TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from           to_________

Commission File Number:             0-6658__________

                       SCIENTIFIC INDUSTRIES, INC.
_____________________________________________________________________
(Exact name of registrant as specified in its charter)

       Delaware         	            04-2217279
____________________________    _________________________________
(State or other jurisdiction	(IRS Employer Identification No.)
 of incorporation or
 organization)

70 Orville Drive, Bohemia, New York                11716
________________________________________        __________
(Address of principal executive offices)	(Zip Code)

                              (631)567-4700
_____________________________________________________________________
(Registrant's telephone number, including area code)

                               Not Applicable
_____________________________________________________________________
(Former name, former address and former fiscal year, if changed since
last report)

Indicate by check whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.   Yes X      No

Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, or a small reporting company.
See the definitions of "large accelerated filer," "accelerated filer" and
"small reporting company" in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ______ 	Accelerated Filer _____

	Non-accelerated filer _______  	Smaller reporting company    X
    (Do not check if a smaller reporting company)                ________

Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).
							Yes    X No
                                                    ____     ____
The number of shares outstanding of the issuer's common stock par value,
$0.05 per share, as of October 25, 2013 was 1,342,663 shares.





				TABLE OF CONTENTS



PART I  - FINANCIAL INFORMATION


ITEM 1	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED):

					                             Page
                                                                     ____
	Condensed Consolidated Balance Sheets		               1

	Condensed Consolidated Statements of Operations	               2

	Condensed Consolidated Statements of Comprehensive
	Income (Loss)	                                               3

	Condensed Consolidated Statements of Cash Flows		       4

  	Notes to Condensed Consolidated Financial Statements	       5

ITEM 2	MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS    12

ITEM 4	CONTROLS AND PROCEDURES                                       14

PART II - OTHER INFORMATION

ITEM 6	EXHIBITS AND REPORTS ON FORM 8-K                              15

SIGNATURE                                                             16

EXHIBITS                                                              17










                     PART I-FINANCIAL INFORMATION


Item 1.  Financial Statements

             SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
               CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS
                                                  September 30,   June 30,
                                           	       2013         2013
                                                    ___________ __________
Current Assets:		                            (Unaudited)
  Cash and cash equivalents			    $  732,700  $  927,300
  Investment securities				       911,500	   908,400
  Trade accounts receivable, net		       815,800	   815,900
  Inventories					     1,783,400	 1,705,600
  Prepaid expenses and other current assets	       105,900	    59,000
  Deferred taxes				        88,000	    86,600
                                                    __________  __________
Total current assets				     4,437,300	 4,502,800

Property and equipment at cost, net		       148,900	   156,500

Intangible assets, net  			       747,300	   773,500

Goodwill					       589,900	   589,900

Other assets            			 	24,100	    24,100

Deferred taxes					       101,600	   106,200
                                                    __________  __________
Total assets                                        $6,049,100	$6,153,000
                                                    ==========  ==========
	LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
  Accounts payable				    $  161,800	$  156,800
  Customer advances				        43,300	    15,900
  Notes payable, current portion			79,000	    78,300
  Accrued expenses and taxes			       289,600	   407,700
  Contingent consideration payable, current portion	19,000	    19,000
  Dividends payable				       107,400	      -
                                                    __________  __________
 		Total current liabilities	       700,100	   677,700

Contingent consideration payable, less current portion	51,600	    51,600

Notes payable, less current portion			 6,700	    26,700
                                                    __________  __________
        Total liabilities			       758,400	   756,000
                                                    __________  __________
Shareholders' equity:
  Common stock, $.05 par value; authorized 7,000,000 shares;
    1,357,465 issued and outstanding at
    September 30, and June 30, 2013    		        67,900	    67,900
  Additional paid-in capital                         1,977,900	 1,977,100
  Accumulated other comprehensive loss             (    15,400)	 (  13,600)
  Retained earnings                                  3,312,700	 3,418,000
                                                   ____________  __________
                                                     5,343,100	 5,449,400
  Less common stock held in treasury, at cost,
   19,802 shares                                        52,400	    52,400
                                                   ____________  __________
Total shareholders' equity                           5,290,700	 5,397,000
Total liabilities and                              ____________ ___________
  shareholders' equity                              $6,049,100	$6,153,000
                                                   ============ ===========



    See notes to unaudited condensed consolidated financial statements

                                      1




SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)




		 			       For the Three Month
					          Periods Ended
					           September 30,
                                            ____________________________
					       2013          	  2012
                                            __________        __________
Revenues                		    $1,436,100        $1,351,700
Cost of sales		     		       841,900           887,300
                                            __________        __________
Gross profit              		       594,200           464,400
                                            __________        __________
Operating Expenses:
 General and administrative		       303,000           279,600
 Selling				       197,000           156,400
 Research and development			97,200           120,100
                                            __________        __________
 	Total operating expenses	       597,200           556,100
                                            __________        __________
Loss from operations			   (     3,000)      (    91,700)
                                            __________        __________
Other income (expense):
 Investment income				 3,100             2,900
 Other income					 3,700		   2,500
 Interest expense			   (       800)      (     1,400)
                                            __________        __________
	Total other income, net			 6,000 	           4,000
                                            __________        __________
Income (loss) before income tax expense
 (benefit)					 3,000 	     (    87,700)
                                            __________        __________
Income tax expense (benefit):
	Current		  		   (     3,100)      (    30,600)
	Deferred		                 4,000             5,100
                                            __________        __________
	Total income tax expense
      (benefit)				           900       (    25,500)
                                            __________        __________
Net income (loss)		   	    $    2,100       ($   62,200)
                                            ==========        ==========

Basic earnings (loss) per common share      $  .00           ($  .05)
                                            ======            ======
Diluted earnings (loss) per common share    $  .00           ($  .05)
                                            ======            ======
Cash dividends declared
 per common share		  	    $  .08            $  .03
                                            ======            ======



See notes to unaudited condensed consolidated financial statements

                               2





             SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
   CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)



						For the Three Month
						   Periods Ended
						   September 30,
                                                ___________________
						   2013	    2012
                                                ________ __________
Net income (loss)				$  2,100 ($  62,200)

Other comprehensive income (loss):
  Unrealized holding gain (loss)
  arising during period,
  net of tax					(  1,800)     9,600
                                                ________  _________
Comprehensive income (loss)			$    300  ($ 52,600)
                                                ========  =========



See notes to unaudited condensed consolidated financial statements



                                3




         SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


                                      For the Three Month Periods Ended
				       Sept. 30, 2013   Sept. 30, 2012
                                       ______________   ______________
Operating activities:
  Net income (loss)                        $   2,100      ($  62,200)
                                           _________       _________
  Adjustments to reconcile net income (loss)
   to net cash provided by (used in) operating activities:
      Depreciation and amortization          44,200           44,300
      Deferred income taxes		      4,000	       5,100
      Stock-based compensation	                800	       3,400
      Changes in operating assets and liabilities:
         Accounts receivable                    100	  (   15,600)
         Inventories                      (  77,800)      (  134,600)
         Prepaid expenses and other
          current assets                  (  46,900)          17,400
	    Other assets		       -   		 100
         Accounts payable                     5,000           63,900
         Customer advances	 	     27,500          102,400
         Accrued expenses and taxes       ( 118,100)      (    4,400)
                                          _________       __________
       Total adjustments		  ( 161,200)          82,000
                                          _________       __________
       Net cash provided by (used in)
        operating activities	          ( 159,100)          19,800
                                          _________       __________
Investing activities:
  Purchase of investment securities,
    available-for-sale                    (   5,700)      (    2,300)
  Capital expenditures                    (   8,500)      (   17,400)
  Purchases of intangible assets          (   1,900)      (    2,100)
                                          _________       __________
       Net cash used in
	   investing activities		  (  16,100)	  (   21,800)
                                          _________       __________
Financing activities:
  Principal payments on note payable	  (  19,400)	  (   18,700)
                                          _________       __________
Net decrease in cash and
  cash equivalents	 	          ( 194,600)      (   20,700)
Cash and cash equivalents,
  beginning of period	                    927,300          769,300
                                          _________       __________
Cash and cash equivalents, end of period  $ 732,700	  $  748,600
                                          _________       __________
Supplemental disclosures:

Cash paid during the period for:
  Income Taxes		                  $ 100,000       $     -
  Interest			                800	       1,400


See notes to unaudited condensed consolidated financial statements


                               4





SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


General:  The accompanying unaudited interim condensed consolidated
financial statements are prepared pursuant to the Securities
and Exchange Commission's rules and regulations for reporting
on Form 10-Q. Accordingly, certain information and footnotes
required by accounting principles generally accepted in the
United States for complete financial statements are not
included herein. The Company believes all adjustments necessary
for a fair presentation of these interim statements have been
included and that they are of a normal and recurring nature.
These interim statements should be read in conjunction with
the Company's financial statements and notes thereto, included
in its Annual Report on Form 10-K, for the fiscal year ended
June 30, 2013.  The results for the three months ended September
30, 2013, are not necessarily an indication of the results for
the full fiscal year ending June 30, 2014.

1.	Summary of significant accounting policies:

	Principles of consolidation:

The accompanying consolidated financial statements include the
accounts of Scientific Industries, Inc. ("Scientific", a Delaware
corporation), Altamira Instruments, Inc.("Altamira", a wholly owned
subsidiary and Delaware corporation), Scientific Packaging Industries,
Inc. (an inactive wholly owned subsidiary and New York corporation)
and Scientific Bioprocessing, Inc., ("SBI", a wholly owned subsidiary
and Delaware corporation).  All are collectively referred to as the
"Company".  All material intercompany balances and transactions have
been eliminated.

2.	New Accounting Pronouncements:


In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740),
which clarifies the presentation requirements of unrecognized tax
benefits when a net operating loss carry forward, a similar tax loss,
or a tax credit carry forward exists at the reporting date. The
amendments in this ASU are effective for fiscal years, and interim
periods within those years, beginning after December 15, 2013 and
should be applied prospectively. The adoption of this ASU is not
expected to have a material impact to the Company's consolidated
financial statements.



                                    5



3.  Acquisition:

On November 14, 2011, the Company through SBI acquired substantially
all of the assets of a privately owned company consisting principally
of a license and sublicenses under patents held by the University of
Maryland, Baltimore County ("UMBC") with respect to the design,
development and production of bioprocessing methods, systems and
products.   The acquisition was pursuant to an asset purchase
agreement. The Company paid to the seller $260,000 in cash, issued
135,135 shares of Common Stock valued at $400,000, issued to UMBC a
$230,000 36-month note payable, and agreed to make additional cash
payments equal to 30% of net royalties received under the acquired
license and sublicenses, estimated at a present value of $128,000
on the date of acquisition.

SBI's revenues are derived from royalties received by SBI under the
various sublicense agreements, net of royalty payments due to UMBC
and revenues from future sales of certain products being developed
under its existing license.  University, government, and industrial
laboratories working primarily in the biotechnology industry worldwide
are its targeted customers.

Management of the Company allocated the purchase price based on its
valuation of the assets acquired, all of which are intangible, as
follows:

         Technology, trademarks, and in-process
         research & development ("IPR&D")		$  500,000
         Sublicense agreements				   294,000
         Engineering drawings and software 		    64,000
         Non-competition agreements			    18,000
         Goodwill*					   142,000
                                                        __________
         Total Purchase Price				$1,018,000
                                                        ==========
         *See Note 8, "Goodwill and Other Intangible Assets".

The amounts allocated to Technology, Trademarks, and IPR&D and
Sublicense Agreements are deemed to have a useful life of 10 years,
and to the remaining intangible assets to have a useful life of 5
years, all of which are being amortized on a straight-line basis,
except for goodwill.

In connection with the acquisition, SBI entered into a research and
development agreement providing for the seller to perform services
with respect to the research and development of bioprocessing
methods, systems, and products pursuant to programs set forth in the
Agreement at a fee of $14,000 per month plus all related expenses.  The
agreement was terminated in June 2013 as a result of the death of the
seller's chief operating officer.


                                     6




4.   Segment Information and Concentrations:

The Company views its operations as three segments:  the manufacture
and marketing of standard benchtop laboratory equipment for research
in university, hospital and industrial laboratories sold primarily
through laboratory equipment distributors ("Benchtop Laboratory
Equipment"), the manufacture and marketing of custom-made catalyst
research instruments for universities, government laboratories, and
chemical and petrochemical companies sold on a direct basis ("Catalyst
Research Instruments") and the marketing and production of bioprocessing
systems for laboratory research in the biotechnology industry sold
directly to customers and through distributors ("Bioprocessing Systems").


	Segment information is reported as follows:

               Benchtop    Catalyst     Bio-       Corporate
               Laboratory  Research     processing and       Conso-
               Equipment   Instruments  Systems    Other     lidated
               __________  ___________  __________ _________ ___________
Three months ended September 30, 2013:

 Revenues       $1,069,700 $  339,700   $   26,700 $     -   $1,436,100
 Foreign Sales	   620,800     73,500        2,000	 -      696,300
 Income(Loss) from
    Operations     117,800 (  104,000)  (   16,800)      -   (    3,000)
 Assets          2,470,200  1,587,200      890,600  1,101,100 6,049,100
 Long-Lived Asset
    Expenditures     9,900       -             500       -       10,400
 Depreciation and
    Amortization    11,000      9,100       24,100       -       44,200



               Benchtop    Catalyst     Bio-       Corporate
               Laboratory  Research     processing and       Conso-
               Equipment   Instruments  Systems    Other     lidated
               __________  ___________  __________ _________ ___________
Three months ended September 30, 2012:

 Revenues      $1,064,900  $  284,200   $    2,600  $    -   $1,351,700
 Foreign Sales	  621,700     239,200         -          -      860,900
 Income (Loss) from
  Operations      117,600  (  134,300) (    75,000)      -  (    91,700)
 Assets     	2,556,900     987,000      801,000 1,521,200  5,866,100
 Long-Lived Asset
    Expenditures    2,100      17,400          -         -       19,500
 Depreciation and
    Amortization   11,100       9,300       23,900       -       44,300


Approximately 68% and 61% of net sales of benchtop laboratory equipment
for the three month periods ended September 30, 2013 and 2012, respectively,
were derived from the Company's main product, the Vortex-Genie 2(R) mixer,
excluding accessories.



                                       7




Two customers accounted in the aggregate for approximately 15% and 22% of
the net sales of the Benchtop Laboratory Equipment Operations and 11% and
17% of the Company's revenues for the three months ended September 30, 2013,
and 2012, respectively.  Sales of catalyst research instruments generally
comprise a few very large orders averaging at least $100,000 per order to a
limited number of customers, who differ from order to order.  Sales to three
customers during the three months ended September 30, 2013 accounted for
approximately 94% of the Catalyst Research Instrument Operations' revenues
and 22% of the Company's total revenues and to five different customers
for the three months ended September 30, 2012 accounted for 97% of the
segment's revenues and 17% of the Company's total revenues.

The Company's foreign sales are principally to customers in Europe and Asia.

5.	Fair Value of Financial Instruments:

The FASB defines the fair value of financial instruments as the amount that
would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement date.
Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair
value and establishes a fair value hierarchy of valuation inputs.  The
hierarchy prioritizes the inputs into three levels based on the extent to
which inputs used in measuring fair value are observable in the market.
Each fair value measurement is reported in one of the three levels, which
is determined by the lowest level input that is significant to the fair
value measurement in its entirety.  These levels are described below:

Level 1   Inputs that are based upon unadjusted quoted prices for
identical instruments traded in active markets.

Level 2	  Quoted prices in markets that are not considered to be
active or financial instruments for which all significant inputs are
observable, either directly or indirectly.

Level 3   Prices or valuation that require inputs that are both significant
to the fair value measurement and unobservable.

The following tables set forth by level within the fair value hierarchy
the Company's financial assets that were accounted for at fair value on a
recurring basis at September 30, 2013 and June 30, 2013 according to the
valuation techniques the Company used to determine their fair values:


                                    Fair Value Measurements Using Inputs
                                                Considered as

Assets:
                            Fair Value at
                         September 30, 2013   Level 1   Level 2  Level 3
                            ______________  __________ _______  ________


Cash and cash equivalents	$  732,700  $  732,700  $  -    $  -
Available for sale securities      911,500     911,500     -       -
                                __________  __________  _______ ________
Total			        $1,644,200  $1,644,200  $  -    $  -
                                ==========  ==========  ======= ========
Liabilities:

Contingent consideration        $   70,600  $    -      $  -   	$ 70,600
                                ==========  ==========  ======= ========


                                            8





                                    Fair Value Measurements Using Inputs
                                                Considered as

Assets:
                            Fair Value at
                            June 30, 2013   Level 1    Level 2  Level 3
                            ______________  __________ _______  ________


Cash and cash equivalents	$  927,300  $  927,300  $  -    $  -
Available for sale securities      908,400     908,400     -       -
                                __________  __________  _______ ________
Total			        $1,835,700  $1,835,700  $  -    $  -
                                ==========  ==========  ======= ========
Liabilities:

Contingent consideration        $   70,600  $    -      $  -   	$ 70,600
                                ==========  ==========  ======= ========

Investments in marketable securities classified as available-for-sale by
security type at September 30, 2013 and June 30, 2013 consisted of the
following:


                                                            Unrealized
                                               	    Fair   Holding Gain
                                        Cost        Value     (Loss)
	                           ____________  _________ ____________
At September 30, 2013:

   Available for sale:
   Equity securities		     $  29,300	$  32,400   $   3,100
   Mutual funds			       897,600	  879,100     (18,500)
                                     _________  _________   __________
				     $ 926,900	$ 911,500   $ (15,400)
                                     =========  =========   ==========


                                                            Unrealized
                                               	    Fair   Holding Gain
                                        Cost        Value     (Loss)
	                           ____________  _________ ____________

At June 30, 2013:

       Available for sale:
       Equity securities            $   29,300   $  33,200  $   3,900
       Mutual funds                    892,700     875,200    (17,500)
                                    __________   _________  __________
                                    $  922,000   $ 908,400  $ (13,600)
                                    ==========   =========  ==========
6.	Inventories:

Inventories for financial statement purposes are based on perpetual
inventory records at September 30, 2013 and based on a physical count as
of June 30, 2013.  Components of inventory are as follows:

			    September 30,  	June 30,
				2013   		  2013
                            _____________       __________
	Raw Materials         $1,326,200	$1,336,800
	Work in process          331,900    	   254,000
	Finished Goods           125,300	   114,800
                              __________        __________
			      $1,783,400	$1,705,600
                              ==========        ==========



                                 9




7.   Earnings (Loss) per common share:

Basic earnings (loss) per common share are computed by dividing net
income or loss by the weighted-average number of shares outstanding.
Diluted earnings per common share include the dilutive effect of stock
options, if any.

Earnings (Loss) per common share was computed as follows:

                           	    For the Three Month
                           	    Periods Ended
                             	    September 30,
                                    __________________________
       					2013          2012
                                    ___________  _____________
	Net income (loss)	    $     2,100  ($    62,200)
                                    ===========  =============
	Weighted average common
 	  shares outstanding	      1,337,663     1,335,712
	Dilutive  securities	          7,408	        -
                                    ___________  _____________
	Weighted average dilutive
	  common shares outstanding   1,345,071     1,335,712
                                    ___________  _____________
	  Basic earnings (loss) per
	  common share		    $   .00 	  ($   .05)

	Diluted earnings (loss) per
	  common share		    $   .00 	  ($   .05)

Approximately 28,500 and 60,000 shares of the Company's Common Stock
issuable upon the exercise of outstanding stock options were excluded from
the calculation of diluted earnings per common share for the three months
ended September 30, 2013 and 2012, respectively, because the effect would
be anti-dilutive.

8.   Goodwill and Other Intangible Assets:

Goodwill represents the excess of the purchase price over the fair value
of the net assets acquired in connection with the Company's acquisition of
Altamira and SBI's acquisition of assets.  Goodwill amounted to $589,900
as of September 30, 2013 and June 30, 2013, all of which is expected to be
deductible for tax purposes.

 The components of other intangible assets are as follows:


			  Useful                Accumulated
			  Lives        Cost     Amortization      Net
                         _________  _________   ____________  _________
 At September 30, 2013:

 Technology, trademarks  5/10 yrs.  $ 865,900   $   417,800   $ 448,100
 Customer relationships   10 yrs.     237,000 	    205,600      31,400
 Sublicense agreements    10 yrs.     294,000        55,100	238,900
 Non-compete agreements    5 yrs.     114,000       106,500       7,500
 Other intangible assets   5 yrs.     157,400       136,000      21,400
                                   __________    __________   _________
	  			   $1,668,300    $  921,000   $ 747,300
                                   ==========    ==========   =========

                                           10

			Useful                  Accumulated
			Lives          Cost     Amortization      Net
                        __________  _________   ____________  _________
 At June 30, 2013:

 Technology, trademarks  5/10 yrs.  $ 865,400   $   402,100   $ 463,300
 Customer relationships   10 yrs.     237,000 	    203,200      33,800
 Sublicense agreements    10 yrs.     294,000        47,800     246,200
 Non-compete agreements    5 yrs.     114,000       105,900       8,100
 Other intangible assets   5 yrs.     156,000       133,900      22,100
                                   __________    __________   _________
	  			   $1,666,400    $  892,900   $ 773,500
                                   ==========    ==========   =========

Total amortization expense was $28,100 and $28,800 for the three months
ended September 30, 2013 and 2012, respectively.  As of September 30,
2013, estimated future amortization expense related to intangible assets
is $82,700 for the remainder of the fiscal year ending June 30, 2014,
$106,600 for fiscal 2015, $110,800 for fiscal 2016, $95,600 for fiscal
2017, $81,100 for fiscal 2018, and $270,500 thereafter.





                                    11


             SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES


Item 2. Management's Discussion and Analysis or Plan of Operations

Certain statements contained in this report are not based on historical
facts, but are forward-looking statements that are based upon various
assumptions about future conditions.  Actual events in the future could
differ materially from those described in the forward-looking information.
Numerous unknown factors and future events could cause such differences,
including but not limited to, product demand, market acceptance, impact
of competition, the ability to reach final agreements, the ability to
finance and produce to customers' specifications catalyst research
instruments, and to develop marketable bioprocessing systems, adverse
economic conditions, and other factors affecting the Company's business
that are beyond the Company's control.  Consequently, no forward-looking
statement can be guaranteed.

We undertake no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or
otherwise.

Liquidity and Capital Resources

Cash and cash equivalents decreased by $194,600 to $732,700 as of
September 30, 2013 from $927,300 as of June 30, 2013.

Net cash used in operating activities was $159,100 for the three months
ended September 30, 2013 as compared to cash provided by operating
activities of $19,800 for the comparable three month period in 2012,
due mainly to the income tax payments made and lower cash advances in
the current period compared to the prior period. Cash used in investing
activities was $16,100 for the three month period ended September 30,
2013 compared to $21,800 for the three month period ended September 30,
2012 due primarily to decreased capital expenditures.  Cash used in
financing activities was $19,400 and $18,700 for the three months ended
September 30, 2013 and 2012, respectively, related to principal payments
on a note related to a recent acquisition.

On September 20, 2013, the Board of Directors of the Company declared a
cash dividend of $.08 per share of Common Stock payable on November 4,
2013 to holders of record as of the close of business on October 11,
2013.

The Company's working capital decreased by $87,900 to $3,737,200 at
September 30, 2013 from $3,825,100 at June 30, 2013, mostly due to the
dividend declared during the period.

The Company has a line of credit with its bank, JPMorgan Chase Bank,
N.A. which provides for maximum borrowings of up to $700,000, bearing
interest at 3.05 percentage points above a defined LIBOR Index. The
interest rate as of September 30, 2013 was approximately 3.25% and is
to be secured by a pledge of collateral consisting of the inventory,
accounts, chattel paper, equipment and general intangibles of the
Company.  Outstanding amounts are due and payable by June 14, 2014
with a requirement that the Company is to reduce the outstanding
principal balance to zero during the 30 day period ending on the
anniversary date of the promissory note.  As of September 30, 2013
and June 30, 2013, no borrowings under the line were outstanding.


			   12





Management believes that the Company will be able to meet its cash
flow needs during the next 12 months from its available financial
resources which include its cash and investment securities.

Results of Operations

Financial Overview

The Company recorded income of $3,000 before income tax expense for
the three months ended September 30, 2013 compared to a loss of
$87,700 before income tax benefit for the comparable period last year;
the improvement, primarily the result of a smaller loss by the
Bioprocessing Systems Operations due to lower research and development
expenses during the current year period.  The Catalyst Research
Instruments Operations also incurred a smaller loss in the current
year period primarily due to higher sales.

The Three Months Ended September 30, 2013 Compared With the Three
Months Ended September 30, 2012

Revenues for the three months ended September 30, 2013 increased by
$84,400 (6.2%) to $1,436,100 from $1,351,700 for the three months
ended September 30, 2012, primarily as a result of a $55,500 increase
in catalyst research instrument sales and a $24,100 increase in revenue
of the bioprocessing systems operations. Sales of benchtop laboratory
products increased slightly by $4,800 compared to the same period last
year. Sales of catalyst research instruments are sold pursuant to a
small number of larger orders, typically averaging over $100,000 each,
resulting in significant swings in revenues. The Bioprocessing Systems
Operations' revenues consist primarily of earned royalties.  The
backlog of orders for catalyst research instruments was $513,400 as of
September 30, 2013, substantially all of which is expected to be
delivered by fiscal year end, as compared to the backlog as of
September 30, 2012 of $1,240,000.

The gross profit percentage for the three months ended September
30, 2013 increased to 41.4% compared to 34.4% for the three months
ended September 30, 2012, due to product mix.

General and administrative expenses for the three months ended
September 30, 2013 increased by $23,400 (8.4%) to $303,000 from
$279,600 for the three months ended September 30, 2012, primarily
due to an increase in expenses incurred by the Benchtop Laboratory
Equipment Operations.

Selling expenses for the three months ended September 30, 2013
increased $40,600 (26.0%) to $197,000 from $156,400 for the three
months ended September 30, 2012, primarily the result of increased
sales commissions and exhibitions expenses for the Catalyst
Research Instruments Operations.

Research and development expenses for the three months ended
September 30, 2013 decreased by $22,900 (19.1%) to $97,200 from
$120,100 for the three months ended September 30, 2012, primarily
the result of lower product development costs related to the
Bioprocessing Systems Operations during the current quarter
due to the termination of an R&D agreement.



                             13




Other income increased by $2,000 to $6,000 for the three months
ended September 30, 2013 from $4,000 for the prior year period,
mainly due to lower interest expense incurred by the Bioprocessing
Systems Operations and higher miscellaneous income.

For the three months ended September 30, 2013, the income tax
expense was $900 compared to an income tax benefit of $25,500 for
the three months ended September 30, 2012.

As a result, net income for the three months ended September 30, 2013
of $2,100 compared to a net loss of $62,200 for the three months
ended September 30, 2012.



Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures.  As of the end
of the period covered by this report, based on an evaluation of the
Company's disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934),
the Chief Executive and Chief Financial Officer of the Company has
concluded that the Company's disclosure controls and procedures
are effective to ensure that information required to be disclosed by
the Company in its Exchange Act reports is recorded, processed,
summarized and reported within the applicable time periods
specified by the SEC's rules and forms. The Company also concluded
that information required to be disclosed in such reports is
accumulated and communicated to the Company's management, including
its principal executive and principal financial officer, as
appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting. There was no
change in the Company's internal controls over financial reporting
that occurred during the most recently completed fiscal quarter
that materially affected or is reasonably likely to materially
affect the Company's internal controls over financial reporting.




                             14




Part II - OTHER INFORMATION


Item 6.  Exhibits and Reports on Form 8-K

	(a) Exhibit Number:	Description

             31.1		Certification of Chief Executive
Officer and Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.

	     32.1		Certification of Chief Executive
Officer and Chief Financial Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.



	(b) Reports on Form 8-K:

            None






                               15






	SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES



                           SIGNATURE



In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.




                              Scientific Industries, Inc.
                              Registrant


                              /s/ Helena R. Santos
			      ____________________________
                              Helena R. Santos
                              President, Chief Executive Officer
                              and Treasurer
                              Principal Executive, Financial and
                              Accounting Officer

Date: November 14, 2013



                                    16

EX-32

						Exhibit 32.1



                        CERTIFICATION

The undersigned as Chief Executive Officer and Chief Financial
Officer of the Company, does hereby certify that the foregoing
Quarterly Report of SCIENTIFIC INDUSTRIES, INC. (the "Company"),
on Form 10-Q for the period ended September 30,
2013:

	(1)	Fully complies with the requirements of Section
13 or 15 (d) of the Securities Exchange Act of 1934; and

	(2)	Fairly presents, in all material respects, the
financial condition and results of operations of the Company.





November 14, 2013


/s/ Helena R. Santos
____________________
Helena R. Santos
Chief Executive Officer and Chief Financial Officer



A signed original of this written statement required by Section 906
has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff
upon request.

EX-31

						Exhibit 31.1


                          CERTIFICATION

   I, Helena R. Santos, certify that:

1.	I have reviewed this report on Form 10-Q for the quarter
ended September 30, 2013 of Scientific Industries, Inc., a smaller
reporting company (the "Registrant");

2.	Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of operations
and cash flows of the Registrant as of, and for, the periods
presented in this report;

4.	I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15 (f) and 15d-15(f) for the
Registrant and have:

a)	Designed such internal disclosure and procedures, or caused
such controls and procedures to be designed under my supervision,
to ensure that material information relating to the Registrant,
including its consolidated subsidiaries, is made known to me by
others within those entities, particularly during the period in
which this report is being prepared;


b)	Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be
designed under my supervision, to provide reasonable assurance,
regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the Registrant's
disclosure controls and procedures and presented in this report
my conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this
report based on such evaluation; and


d)	Disclosed in this report any change in the Registrant's
internal control over financial reporting that occurred during
the Registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to affect, the Registrant's
internal control over financial reporting; and

5.      I have disclosed, based on my most recent evaluation
of internal controls over financial reporting, to the Registrant's
 auditors and the audit committee of the Registrant?s board of
directors (or persons performing the equivalent functions):

a)	 All significant deficiencies and material weaknesses
in the design or operation of internal controls over financial
reporting which are reasonably likely to adversely affect the
Registrant's ability to record, process, summarize and report
financial information; and
b)	 Any fraud, whether or not material, that involves
management or other employees who have a significant role in
the Registrant's internal controls over financial reporting.

November 14, 2013


/s/ Helena R. Santos
____________________
Helena R. Santos
Chief Executive Officer and Chief Financial Officer

XML

5. Fair Value of Financial Instruments (Tables)

3 Months Ended

Sep. 30, 2013

Investments, All Other Investments [Abstract]

Fair Value Inputs

Assets:
		Fair Value at September 30, 2013		Level 1		Level 2		Level 3
Cash and cash equivalents	$	732,700	$	732,700	$	—	$	—
Available for sale securities		911,500		911,500		—		—
Total	$	1,644,200	$	1,644,200	$	—	$	—
Liabilities:
Contingent consideration	$	70,600	$	—	$	—	$	70,600

Fair Value Measurements Using Inputs Considered as
Assets:
		Fair Value at June 30, 2013		Level 1		Level 2		Level 3
Cash and cash equivalents	$	927,300	$	927,300	$	—	$	—
Available for sale securities		908,400		908,400		—		—
Total	$	1,835,700	$	1,835,700	$	—	$	—
Liabilities:
Contingent consideration	$	70,600	$	—	$	—	$	70,600

Investments in Marketable Securitites

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At September 30, 2013:
Available for sale:
Equity securities	$	29,300	$	32,400	$	3,100
Mutual funds		897,600		879,100		(18,500	)
	$	926,900	$	911,500	$	(15,400	)

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2013:
Available for sale:
Equity securities	$	29,300	$	33,200	$	3,900
Mutual funds		892,700		875,200		(17,500	)
	$	922,000	$	908,400	$	(13,600	)

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Net sales	$ 1,436,100	$ 1,351,700
Cost of sales	841,900	887,300
Gross profit	594,200	464,400
Operating expenses:
General and administrative	303,000	279,600
Selling	197,000	156,400
Research and development	97,200	120,100
Total operating expenses	597,200	556,100
Loss from operations	(3,000)	(91,700)
Other income (expense):
Investment income	3,100	2,900
Other income	3,700	2,500
Interest expense	(800)	(1,400)
Total other income, net	6,000	4,000
Income (loss) before income tax expense (benefit)	3,000	(87,700)
Income tax expense (benefit): Current	(3,100)	(30,600)
Deferred	4,000	5,100
Total income tax expense (benefit)	900	(25,500)
Net income (loss)	$ 2,100	$ (62,200)
Basic earnings (loss) per common share	$ 0	$ (0.05)
Diluted earnings (loss) per common share	$ 0	$ (0.05)
Cash dividends declared	$ 0.08	$ 0.03

XML

4. Segment Information and Concentrations

3 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Information and Concentrations

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors (ABenchtop Laboratory Equipment@), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (ACatalyst Research Instruments@) and the marketing and production of bioprocessing systems for laboratory research in the biotechnology industry sold directly to customers and through distributors (“Bioprocessing Systems”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other		Consolidated
Three months ended September 30, 2013:
Revenues	$	1,069,700	$	339,700		$	26,700		$	0	$	1,436,100
Foreign Sales		620,800		73,500			2,000			0		696,300
Income (Loss) from Operations		117,800		(104,000	)		(16,800	)		0		(3,000	)
Assets		2,470,200		1,587,200			890,600			1,101,100		6,049,100
Long-Lived Asset Expenditures		9,900		0			500			0		10,400
Depreciation and Amortization		11,000		9,100			24,100			0		44,200

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other		Consolidated
Three months ended September 30, 2012:
Revenues	$	1,064,900	$	284,200		$	2,600		$	0	$	1,351,700
Foreign Sales		621,700		239,200			0			0		860,900
Income (Loss) from Operations		117,600		(134,300	)		(75,000	)		0		(91,700	)
Assets		2,556,900		987,000			801,000			1,521,200		5,866,100
Long-Lived Asset Expenditures		2,100		17,400			0			0		19,500
Depreciation and Amortization		11,100		9,300			23,900			0		44,300

Approximately 68% and 61% of net sales of benchtop laboratory equipment for the three month periods ended September 30, 2013 and 2012, respectively, were derived from the Company's main product, the Vortex-Genie 2(R) mixer, excluding accessories. Two customers accounted in the aggregate for approximately 15% and 22% of the net sales of the Benchtop Laboratory Equipment Operations and 11% and 17% of the Company’s revenues for the three months ended September 30, 2013, and 2012, respectively. Sales of catalyst research instruments generally comprise a few very large orders averaging at least $100,000 per order to a limited number of customers, who differ from order to order. Sales to three customers during the three months ended September 30, 2013 accounted for approximately 94% of the Catalyst Research Instrument Operations’ revenues and 22% of the Company’s total revenues and to five different customers for the three months ended September 30, 2012 accounted for 97% of the segment’s revenues and 17% of the Company’s total revenues.

The Company’s foreign sales are principally to customers in Europe and Asia.

XML

5. Fair Value of Financial Instruments (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2012
Cash and cash equivalents	$ 732,700	$ 927,300	$ 748,600	$ 769,300
Available for sale securities	911,500	908,400
Total	911,500	908,400
Liabilities:
Contingent consideration	70,600	70,600
Level 1
Cash and cash equivalents	732,700		927,300
Available for sale securities	911,500		908,400
Total	1,644,200		1,835,700
Liabilities:
Contingent consideration
Level 2
Cash and cash equivalents
Available for sale securities
Total
Liabilities:
Contingent consideration
Level 3
Cash and cash equivalents
Available for sale securities
Total
Liabilities:
Contingent consideration	$ 70,600		$ 70,600

XML

6. Inventories (Tables)

3 Months Ended

Sep. 30, 2013

Inventory Disclosure [Abstract]

Inventories

	September 30, 2013		June 30, 2013
Raw Materials	$	1,326,200	$	1,336,800
Work in process		331,900		254,000
Finished Goods		125,300		114,800
	$	1,783,400	$	1,705,600

XML

7. Earnings (Loss) per common share (Details) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Loss Per Common Share Details
Net income/(loss)	$ 2,100	$ (62,200)
Weighted average common shares outstanding	7,408
Effect of dilutive securities	7,408
Weighted average dilutive common shares outstanding	1,345,071	1,335,712
Basic earnings/(loss) per common share	$ 0	$ (0.05)
Diluted earnings/(loss) per common share	$ 0	$ (0.05)

XML

6. Inventories (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Inventories Details
Raw materials	$ 1,326,200	$ 1,336,800
Work-in-process	331,900	254,000
Finished goods	125,300	114,800
Inventory	$ 1,783,400	$ 1,705,600

XML

5. Fair Value of Financial Instruments (Details 1) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013 Equity Securities	Jun. 30, 2012 Equity Securities	Sep. 30, 2013 Mutual Funds	Jun. 30, 2012 Mutual Funds
Cost	$ 926,900	$ 922,000	$ 29,300	$ 29,300	$ 897,600	$ 892,700
Fair Value	911,500	908,400	32,400	33,200	879,100	875,200
Unrealized Holding Gain (Loss)	$ (15,400)	$ (13,600)	$ 3,100	$ 3,900	$ (18,500)	$ (17,500)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities:
Net income (loss)	$ 2,100	$ (62,200)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation and amortization	44,200	44,300
Deferred income taxes	4,000	5,100
Stock-based compensation	800	3,400
Changes in operating assets and liabilities:
Accounts receivable	100	(15,600)
Inventories	(77,800)	(134,600)
Prepaid expenses and other current assets	(46,900)	17,400
Other assets		100
Accounts payable	5,000	63,900
Customer advances	27,500	102,400
Accrued expenses and taxes	(118,100)	(4,400)
Total adjustments	(161,200)	82,000
Net cash provided by (used in) operating activities	(159,100)	19,800
Investing activities:
Purchase of investment securities, available for sale	(5,700)	(2,300)
Capital expenditures	(8,500)	(17,400)
Purchases of intangible assets	(1,900)	(2,100)
Net cash used in investing activities	(16,100)	(21,800)
Financing activities:
Principal payments on note payable	(19,400)	(18,700)
Net decrease in cash and cash equivalents	(194,600)	(20,700)
Cash and cash equivalents, beginning of year	927,300	769,300
Cash and cash equivalents, end of period	732,700	748,600
Cash paid during the period for:
Income Taxes	100,000
Interest	$ 800	$ 1,400

XML

2. New Accounting Pronouncements

3 Months Ended

Sep. 30, 2013

Notes to Financial Statements

New Accounting Pronouncements

In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740), which clarifies the presentation requirements of unrecognized tax benefits when a net operating loss carry forward, a similar tax loss, or a tax credit carry forward exists at the reporting date. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively. The adoption of this ASU is not expected to have a material impact to the Company’s consolidated financial statements.

XML

5. Fair Value of Financial Instruments

3 Months Ended

Sep. 30, 2013

Investments, All Other Investments [Abstract]

Fair Value of Financial Instruments

The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy of valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at September 30, 2013 and June 30, 2013 according to the valuation techniques the Company used to determine their fair values:

Fair Value Measurements Using Inputs Considered as
Assets:
		Fair Value at September 30, 2013		Level 1		Level 2		Level 3
Cash and cash equivalents	$	732,700	$	732,700	$	—	$	—
Available for sale securities		911,500		911,500		—		—
Total	$	1,644,200	$	1,644,200	$	—	$	—
Liabilities:
Contingent consideration	$	70,600	$	—	$	—	$	70,600

Fair Value Measurements Using Inputs Considered as
Assets:
		Fair Value at June 30, 2013		Level 1		Level 2		Level 3
Cash and cash equivalents	$	927,300	$	927,300	$	—	$	—
Available for sale securities		908,400		908,400		—		—
Total	$	1,835,700	$	1,835,700	$	—	$	—
Liabilities:
Contingent consideration	$	70,600	$	—	$	—	$	70,600

Investments in marketable securities classified as available-for-sale by security type at September 30, 2013 and June 30, 2013 consisted of the following:

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At September 30, 2013:
Available for sale:
Equity securities	$	29,300	$	32,400	$	3,100
Mutual funds		897,600		879,100		(18,500	)
	$	926,900	$	911,500	$	(15,400	)

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2013:
Available for sale:
Equity securities	$	29,300	$	33,200	$	3,900
Mutual funds		892,700		875,200		(17,500	)
	$	922,000	$	908,400	$	(13,600	)

XML

3. Acquisition

3 Months Ended

Sep. 30, 2013

Text Block [Abstract]

Acquisition

On November 14, 2011, the Company through SBI acquired substantially all of the assets of a privately owned company consisting principally of a license and sublicenses under patents held by the University of Maryland, Baltimore County (“UMBC”) with respect to the design, development and production of bioprocessing methods, systems and products. The acquisition was pursuant to an asset purchase agreement. The Company paid to the seller $260,000 in cash, issued 135,135 shares of Common Stock valued at $400,000, issued to UMBC a $230,000 36-month note payable, and agreed to make additional cash payments equal to 30% of net royalties received under the acquired license and sublicenses, estimated at a present value of $128,000 on the date of acquisition. 

SBI’s revenues are derived from royalties received by SBI under the various sublicense agreements, net of royalty payments due to UMBC and revenues from future sales of certain products being developed under its existing license. University, government, and industrial laboratories working primarily in the biotechnology industry worldwide are its targeted customers.

Management of the Company allocated the purchase price based on its valuation of the assets acquired, all of which are intangible, as follows:

Technology, trademarks, and in-process research & development ("IPR&D")	$	500,000
Sublicense agreements		294,000
Engineering drawings and software		64,000
Non-competition agreements		18,000
Goodwill*		142,000
Total Purchase Price	$	1,018,000

*See Note 8, “Goodwill and Other Intangible Assets”.

 The amounts allocated to Technology, Trademarks, and IPR&D and Sublicense Agreements are deemed to have a useful life of 10 years, and to the remaining intangible assets to have a useful life of 5 years, all of which are being amortized on a straight-line basis, except for goodwill.

 In connection with the acquisition, SBI entered into a research and development agreement providing for the seller to perform services with respect to the research and development of bioprocessing methods, systems, and products pursuant to programs set forth in the Agreement at a fee of $14,000 per month plus all related expenses. The agreement was terminated in June 2013 as a result of the death of the seller’s chief operating officer.

XML

7. Earnings (Loss) per common share (Details Narrative)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Equity [Abstract]
Common stock issuable upon the exercise of outstanding options	28,500	60,000

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Shareholders' equity:
Common stock,par value	$ 0.05	$ 0.05
Common stock, authorized shares	7,000,000	7,000,000
Common stock, issued shares	1,357,465	1,357,465
Common stock, outstanding shares	1,357,465	1,357,465
Stock held in treasury, shares	19,802	19,802

XML

8. Goodwill and Other Intangible Assets

3 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company's acquisition of Altamira and SBI’s acquisition of assets. Goodwill amounted to $589,900 as of September 30, 2013 and June 30, 2013, all of which is expected to be deductible for tax purposes.

The components of other intangible assets are as follows:

	Useful Lives	Cost		Accumulated Amortization		Net
At September 30, 2013:
Technology, trademarks	5/10 yrs.	$	865,900	$	417,800	$	448,100
Customer relationships	10 yrs.		237,000		205,600	$	31,400
Sublicense agreements	10 yrs.		294,000		55,100	$	238,900
Non-compete agreements	5 yrs.		114,000		106,500	$	7,500
Other intangible assets	5 yrs.		157,400		136,000	$	21,400
		$	1,668,300	$	921,000	$	747,300

	Useful Lives	Cost		Accumulated Amortization		Net
At June 30, 2013:
Technology, trademarks	5/10 yrs.	$	865,400	$	402,100	$	463,300
Customer relationships	10 yrs.		237,000		203,200	$	33,800
Sublicense agreements	10 yrs.		294,000		47,800	$	246,200
Non-compete agreements	5 yrs.		114,000		105,900	$	8,100
Other intangible assets	5 yrs.		156,000		133,900	$	22,100
		$	1,666,400	$	892,900	$	773,500

Total amortization expense was $28,100 and $28,800 for the three months ended September 30, 2013 and 2012, respectively. As of September 30, 2013, estimated future amortization expense related to intangible assets is $82,700 for the remainder of the fiscal year ending June 30, 2014, $106,600 for fiscal 2015, $110,800 for fiscal 2016, $95,600 for fiscal 2017, $81,100 for fiscal 2018, and $270,500 thereafter.

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Condensed Consolidated Statements Of Comprehensive Income Loss
Net income (loss)	$ 2,100	$ (62,200)
Other comprehensive income (loss):
Unrealized holding gain (loss) arising during period, net of tax	(1,800)	9,600
Comprehensive income (loss)	$ 300	$ (52,600)

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Jun. 30, 2013
Current Assets:
Cash and cash equivalents	$ 732,700	$ 927,300
Investment securities	911,500	908,400
Trade accounts receivable, net	815,800	815,900
Inventories	1,783,400	1,705,600
Prepaid expenses and other current assets	105,900	59,000
Deferred taxes	88,000	86,600
Total current assets	4,437,300	4,502,800
Property and equipment at cost, net	148,900	156,500
Intangible assets, net	747,300	773,500
Goodwill	589,900	589,900
Other assets	24,100	24,100
Deferred taxes	101,600	106,200
Total assets	6,049,100	6,153,000
Current Liabilities:
Accounts payable	161,800	156,800
Customer advances	43,300	15,900
Notes payable, current	79,000	78,300
Accrued expenses and taxes	289,600	407,700
Contingent consideration payable, current portion	19,000	19,000
Dividends payable	107,400
Total current liabilities	700,100	677,700
Contingent consideration payable, less current portion	51,600	51,600
Notes payable, less current portion	6,700	26,700
Total liabilities	758,400	756,000
Shareholders' equity:
Common stock, $.05 par value; authorized 7,000,000 shares; 1,357,465 issued and outstanding at September 30, 2013 and June 30, 2013.	67,900	67,900
Additional paid-in capital	1,977,900	1,977,100
Accumulated other comprehensive income (loss)	(15,400)	(13,600)
Retained earnings	3,312,700	3,418,000
Total	5,343,100	5,449,400
Less common stock held in treasury at cost, 19,802 shares	52,400	52,400
Total shareholders' equity	5,290,700	5,397,000
Total liabilities and shareholders' equity	$ 6,049,100	$ 6,153,000

XML

8. Goodwill and Other Intangible Assets (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013 Technology, trademarks	Sep. 30, 2012 Technology, trademarks	Sep. 30, 2013 Customer relationships	Sep. 30, 2012 Customer relationships	Sep. 30, 2013 Sublicense agreements	Sep. 30, 2012 Sublicense agreements	Sep. 30, 2013 Non-compete agreements	Sep. 30, 2012 Non-compete agreements	Sep. 30, 2013 Other intangible assets	Sep. 30, 2012 Other intangible assets
Useful Lives Minimum			5 years	5 years
Useful Lives Maximum			10 years	10 years	10 years	10 years	10 years	10 years	5 years	5 years	5 years	5 years
Cost	$ 1,668,300	$ 1,666,400	$ 865,900	$ 865,400	$ 237,000	$ 237,000	$ 294,000	$ 294,000	$ 114,000	$ 114,000	$ 157,400	$ 156,000
Accumulated Amortization	921,000	892,900	417,800	402,100	205,600	203,200	55,100	47,800	106,500	105,900	136,000	133,900
Net	$ 747,300	$ 773,500	$ 448,100	$ 463,300	$ 31,400	$ 33,800	$ 238,900	$ 246,200	$ 7,500	$ 8,100	$ 21,400	$ 22,100

XML

4. Segment Information and Concentrations (Details Narrative)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Benchtop Laboratory Equipment [Member]
Net sales	68.00%	61.00%
TwoCustomers [Member] | Benchtop Laboratory Equipment [Member]
Net sales	15.00%	22.00%
Consolidated sales	11.00%	17.00%
Three Customers [Member] | Catalyst Research Instruments [Member]
Net sales	94.00%
Consolidated sales	22.00%
Five Customers [Member] | Catalyst Research Instruments [Member]
Net sales		97.00%
Consolidated sales		17.00%

XML

7. Earnings (Loss) per common share

3 Months Ended

Sep. 30, 2013

Equity [Abstract]

Earnings (Loss) per common share

Basic earnings (loss) per common share are computed by dividing net income or loss by the weighted-average number of shares outstanding. Diluted earnings per common share include the dilutive effect of stock options, if any.

Earnings (Loss) per common share was computed as follows:

	For the Three Month
	Periods Ended
	September 30,
	2013		2012
Net income (loss)	$	2,100	$	(62,200	)
Weighted average common shares outstanding		1,337,663		1,335,712
Dilutive securities		7,408		—
Weighted average dilutive common shares outstanding		1,345,071		1,335,712
Basic earnings (loss) per common share			$	(0.05	)
Diluted earnings (loss) per common share	$	—	$	(0.05	)

Approximately 28,500 and 60,000 shares of the Company’s Common Stock issuable upon the exercise of outstanding stock options were excluded from the calculation of diluted earnings per common share for the three months ended September 30, 2013 and 2012, respectively, because the effect would be anti-dilutive.

XML

8. Goodwill and Other Intangible Assets (Details Narrative) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013
Goodwill And Other Intangible Assets Details Narrative
Estimated future amortization expense 2013	$ 82,700
Estimated future amortization expense 2014	106,600
Estimated future amortization expense 2015	110,800
Estimated future amortization expense 2016	95,600
Estimated future amortization expense 2017	81,100
Estimated future amortization expense 2018	270,500
Total amortization expense	28,100	28,800
Goodwill	$ 589,900		$ 589,900

XML

4. Segment Information and Concentrations (Tables)

3 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Information

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other		Consolidated
Three months ended September 30, 2013:
Revenues	$	1,069,700	$	339,700		$	26,700		$	0	$	1,436,100
Foreign Sales		620,800		73,500			2,000			0		696,300
Income (Loss) from Operations		117,800		(104,000	)		(16,800	)		0		(3,000	)
Assets		2,470,200		1,587,200			890,600			1,101,100		6,049,100
Long-Lived Asset Expenditures		9,900		0			500			0		10,400
Depreciation and Amortization		11,000		9,100			24,100			0		44,200

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other		Consolidated
Three months ended September 30, 2012:
Revenues	$	1,064,900	$	284,200		$	2,600		$	0	$	1,351,700
Foreign Sales		621,700		239,200			0			0		860,900
Income (Loss) from Operations		117,600		(134,300	)		(75,000	)		0		(91,700	)
Assets		2,556,900		987,000			801,000			1,521,200		5,866,100
Long-Lived Asset Expenditures		2,100		17,400			0			0		19,500
Depreciation and Amortization		11,100		9,300			23,900			0		44,300

XML

6. Inventories

3 Months Ended

Sep. 30, 2013

Inventory Disclosure [Abstract]

Inventories

Inventories for financial statement purposes are based on perpetual inventory records at September 30, 2013 and based on a physical count as of June 30, 2013. Components of inventory are as follows:

	September 30, 2013		June 30, 2013
Raw Materials	$	1,326,200	$	1,336,800
Work in process		331,900		254,000
Finished Goods		125,300		114,800
	$	1,783,400	$	1,705,600

XML

1. Summary of significant accounting policies

3 Months Ended

Sep. 30, 2013

Notes to Financial Statements

Summary of significant accounting policies

Principles of consolidation:

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc. (“Scientific”, a Delaware corporation), Altamira Instruments, Inc.(“Altamira”, a wholly owned subsidiary and Delaware corporation), Scientific Packaging Industries, Inc. (an inactive wholly owned subsidiary and New York corporation) and Scientific Bioprocessing, Inc., (“SBI”, a wholly owned subsidiary and Delaware corporation). All are collectively referred to as the “Company”. All material intercompany balances and transactions have been eliminated.

XML

7. Earnings (Loss) per common share (Tables)

3 Months Ended

Sep. 30, 2013

Equity [Abstract]

Earnings per common share

	For the Three Month
	Periods Ended
	September 30,
	2013		2012
Net income (loss)	$	2,100	$	(62,200	)
Weighted average common shares outstanding		1,337,663		1,335,712
Dilutive securities		7,408		—
Weighted average dilutive common shares outstanding		1,345,071		1,335,712
Basic earnings (loss) per common share			$	(0.05	)
Diluted earnings (loss) per common share	$	—	$	(0.05	)

XML

3. Acquisition (Tables)

3 Months Ended

Sep. 30, 2013

Text Block [Abstract]

Purchase Price Allocation

Technology, trademarks, and in-process research & development ("IPR&D")	$	500,000
Sublicense agreements		294,000
Engineering drawings and software		64,000
Non-competition agreements		18,000
Goodwill*		142,000
Total Purchase Price	$	1,018,000

XML

4. Segment Information and Concentrations (Details) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Depreciation and Amortization	$ 44,200	$ 44,300
Benchtop Laboratory Equipment [Member]
Revenues	1,069,700	1,064,900
Foreign Sales	620,800	621,700
Income (Loss) from Operations	117,800	117,600
Assets	2,470,200	2,556,900
Long-lived Asset Expenditures	9,900	2,100
Depreciation and Amortization	11,000	11,100
Catalyst Research Instruments [Member]
Revenues	339,700	284,200
Foreign Sales	73,500	239,200
Income (Loss) from Operations	(104,000)	(134,300)
Assets	1,587,200	987,000
Long-lived Asset Expenditures	0	17,400
Depreciation and Amortization	9,100	9,300
Bioprocessing Systems [Member]
Revenues	26,700	2,600
Foreign Sales	2,000	0
Income (Loss) from Operations	(16,800)	(75,000)
Assets	890,600	801,000
Long-lived Asset Expenditures	500	0
Depreciation and Amortization	24,100	23,900
Corporate and Other [Member]
Revenues	0	0
Foreign Sales	0	0
Income (Loss) from Operations	0	0
Assets	1,101,100	1,521,200
Long-lived Asset Expenditures	0	0
Depreciation and Amortization	0	0
Consolidated [Member]
Revenues	1,436,100	1,351,700
Foreign Sales	696,300	860,900
Income (Loss) from Operations	(3,000)	(91,700)
Assets	6,049,100	5,866,100
Long-lived Asset Expenditures	10,400	19,500
Depreciation and Amortization	$ 44,200	$ 44,300

XML

8. Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Sep. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

	Useful Lives	Cost		Accumulated Amortization		Net
At September 30, 2013:
Technology, trademarks	5/10 yrs.	$	865,900	$	417,800	$	448,100
Customer relationships	10 yrs.		237,000		205,600	$	31,400
Sublicense agreements	10 yrs.		294,000		55,100	$	238,900
Non-compete agreements	5 yrs.		114,000		106,500	$	7,500
Other intangible assets	5 yrs.		157,400		136,000	$	21,400
		$	1,668,300	$	921,000	$	747,300

	Useful Lives	Cost		Accumulated Amortization		Net
At June 30, 2013:
Technology, trademarks	5/10 yrs.	$	865,400	$	402,100	$	463,300
Customer relationships	10 yrs.		237,000		203,200	$	33,800
Sublicense agreements	10 yrs.		294,000		47,800	$	246,200
Non-compete agreements	5 yrs.		114,000		105,900	$	8,100
Other intangible assets	5 yrs.		156,000		133,900	$	22,100
		$	1,666,400	$	892,900	$	773,500

XML

Document and Entity Information	3 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document And Entity Information
Entity Registrant Name	SCIENTIFIC INDUSTRIES INC
Entity Central Index Key	0000087802
Document Type	10-Q
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		1,342,663
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2014

XML

3. Acquisition (Details) (USD $)	Sep. 30, 2013
Acquisition Details
Technology, trademarks, and in-process research & development ("IPR&D")	$ 500,000
Sublicense agreements	294,000
Engineering drawings and software	64,000
Non-competition agreements	18,000
Goodwill	142,000
Total Purchase Price	$ 1,018,000